Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Prutsch N, Gurnhofer E, Suske T, Liang HC, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, Look AT, Turner SD, Kenner L, Merkel O.

Leukemia. 2018 Aug 21. doi: 10.1038/s41375-018-0239-1. [Epub ahead of print]

PMID:
30131584
2.

STAT3 isoforms: Alternative fates in cancer?

Aigner P, Just V, Stoiber D.

Cytokine. 2018 Jul 18. pii: S1043-4666(18)30300-4. doi: 10.1016/j.cyto.2018.07.014. [Epub ahead of print] Review.

3.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
4.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28.

5.

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma.

Rohr-Udilova N, Bauer E, Timelthaler G, Eferl R, Stolze K, Pinter M, Seif M, Hayden H, Reiberger T, Schulte-Hermann R, Peck-Radosavljevic M, Stoiber D, Trauner M.

Oncotarget. 2018 Jan 22;9(11):10054-10068. doi: 10.18632/oncotarget.24300. eCollection 2018 Feb 9.

6.

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.

Perugorria MJ, Esparza-Baquer A, Oakley F, Labiano I, Korosec A, Jais A, Mann J, Tiniakos D, Santos-Laso A, Arbelaiz A, Gawish R, Sampedro A, Fontanellas A, Hijona E, Jimenez-Agüero R, Esterbauer H, Stoiber D, Bujanda L, Banales JM, Knapp S, Sharif O, Mann DA.

Gut. 2018 Jan 27. pii: gutjnl-2017-314107. doi: 10.1136/gutjnl-2017-314107. [Epub ahead of print]

7.

AKT3 drives adenoid cystic carcinoma development in salivary glands.

Zboray K, Mohrherr J, Stiedl P, Pranz K, Wandruszka L, Grabner B, Eferl R, Moriggl R, Stoiber D, Sakamoto K, Wagner KU, Popper H, Casanova E, Moll HP.

Cancer Med. 2018 Feb;7(2):445-453. doi: 10.1002/cam4.1293. Epub 2017 Dec 28.

8.

Natural killer cell-intrinsic type I IFN signaling controls Klebsiella pneumoniae growth during lung infection.

Ivin M, Dumigan A, de Vasconcelos FN, Ebner F, Borroni M, Kavirayani A, Przybyszewska KN, Ingram RJ, Lienenklaus S, Kalinke U, Stoiber D, Bengoechea JA, Kovarik P.

PLoS Pathog. 2017 Nov 7;13(11):e1006696. doi: 10.1371/journal.ppat.1006696. eCollection 2017 Nov.

9.

The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell Development.

Post M, Cuapio A, Osl M, Lehmann D, Resch U, Davies DM, Bilban M, Schlechta B, Eppel W, Nathwani A, Stoiber D, Spanholtz J, Casanova E, Hofer E.

Front Immunol. 2017 May 15;8:535. doi: 10.3389/fimmu.2017.00535. eCollection 2017.

10.

Type I Interferons and Natural Killer Cell Regulation in Cancer.

Müller L, Aigner P, Stoiber D.

Front Immunol. 2017 Mar 31;8:304. doi: 10.3389/fimmu.2017.00304. eCollection 2017. Review.

11.

Type I Interferon Signaling Prevents IL-1β-Driven Lethal Systemic Hyperinflammation during Invasive Bacterial Infection of Soft Tissue.

Castiglia V, Piersigilli A, Ebner F, Janos M, Goldmann O, Damböck U, Kröger A, Weiss S, Knapp S, Jamieson AM, Kirschning C, Kalinke U, Strobl B, Müller M, Stoiber D, Lienenklaus S, Kovarik P.

Cell Host Microbe. 2016 Mar 9;19(3):375-87. doi: 10.1016/j.chom.2016.02.003.

12.

Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.

Bauer E, Schlederer M, Scheicher R, Horvath J, Aigner P, Schiefer AI, Kain R, Regele H, Hoermann G, Steiner G, Kenner L, Sexl V, Villunger A, Moriggl R, Stoiber D.

Oncotarget. 2016 Mar 15;7(11):12191-205. doi: 10.18632/oncotarget.7687.

13.

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.

Schiefer AI, Kornauth C, Simonitsch-Klupp I, Skrabs C, Masel EK, Streubel B, Vanura K, Walter K, Migschitz B, Stoiber D, Sexl V, Raderer M, Chott A, da Silva MG, Cabecadas J, Müllauer L, Jäger U, Porpaczy E.

Medicine (Baltimore). 2015 Dec;94(52):e2388. doi: 10.1097/MD.0000000000002388.

14.

Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia.

Grausenburger R, Bastelberger S, Eckert C, Kauer M, Stanulla M, Frech C, Bauer E, Stoiber D, von Stackelberg A, Attarbaschi A, Haas OA, Panzer-Grümayer R.

Leuk Lymphoma. 2016 May;57(5):1163-73. doi: 10.3109/10428194.2015.1088650. Epub 2015 Oct 9.

PMID:
26327566
15.

The MAPK-Activated Kinase MK2 Attenuates Dendritic Cell-Mediated Th1 Differentiation and Autoimmune Encephalomyelitis.

Soukup K, Halfmann A, Le Bras M, Sahin E, Vittori S, Poyer F, Schuh C, Luger R, Niederreiter B, Haider T, Stoiber D, Blüml S, Schabbauer G, Kotlyarov A, Gaestel M, Felzmann T, Dohnal AM.

J Immunol. 2015 Jul 15;195(2):541-52. doi: 10.4049/jimmunol.1401663. Epub 2015 Jun 15.

16.

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E.

Nat Commun. 2015 Mar 3;6:6285. doi: 10.1038/ncomms7285.

17.

Methods to study tumor surveillance using tumor cell transplantation into genetically engineered mice.

Bauer E, Witalisz A, Strobl B, Stoiber D.

Methods Mol Biol. 2015;1267:439-56. doi: 10.1007/978-1-4939-2297-0_22.

PMID:
25636483
18.

Type I interferons have opposing effects during the emergence and recovery phases of colitis.

Rauch I, Hainzl E, Rosebrock F, Heider S, Schwab C, Berry D, Stoiber D, Wagner M, Schleper C, Loy A, Urich T, Müller M, Strobl B, Kenner L, Decker T.

Eur J Immunol. 2014 Sep;44(9):2749-60. doi: 10.1002/eji.201344401. Epub 2014 Aug 25.

19.

ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Kantner HP, Warsch W, Delogu A, Bauer E, Esterbauer H, Casanova E, Sexl V, Stoiber D.

Neoplasia. 2013 Nov;15(11):1292-300.

20.

Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance.

Mizutani T, Neugebauer N, Putz EM, Moritz N, Simma O, Zebedin-Brandl E, Gotthardt D, Warsch W, Eckelhart E, Kantner HP, Kalinke U, Lienenklaus S, Weiss S, Strobl B, Müller M, Sexl V, Stoiber D.

Oncoimmunology. 2012 Oct 1;1(7):1027-1037.

21.

A mouse model to identify cooperating signaling pathways in cancer.

Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner HP, Müller M, Kolbe T, Rülicke T, Moriggl R, Kenner L, Stoiber D, Penninger JM, Popper H, Casanova E, Eferl R.

Nat Methods. 2012 Sep;9(9):897-900. doi: 10.1038/nmeth.2130. Epub 2012 Aug 5.

PMID:
22863881
22.

Conditional Stat1 ablation reveals the importance of interferon signaling for immunity to Listeria monocytogenes infection.

Kernbauer E, Maier V, Stoiber D, Strobl B, Schneckenleithner C, Sexl V, Reichart U, Reizis B, Kalinke U, Jamieson A, Müller M, Decker T.

PLoS Pathog. 2012;8(6):e1002763. doi: 10.1371/journal.ppat.1002763. Epub 2012 Jun 14.

23.

Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias.

Schneckenleithner C, Bago-Horvath Z, Dolznig H, Neugebauer N, Kollmann K, Kolbe T, Decker T, Kerjaschki D, Wagner KU, Müller M, Stoiber D, Sexl V.

Oncotarget. 2011 Dec;2(12):1043-54.

24.

Antagonistic effects of selenium and lipid peroxides on growth control in early hepatocellular carcinoma.

Rohr-Udilova N, Sieghart W, Eferl R, Stoiber D, Björkhem-Bergman L, Eriksson LC, Stolze K, Hayden H, Keppler B, Sagmeister S, Grasl-Kraupp B, Schulte-Hermann R, Peck-Radosavljevic M.

Hepatology. 2012 Apr;55(4):1112-21. doi: 10.1002/hep.24808.

PMID:
22105228
25.

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.

Fuka G, Kantner HP, Grausenburger R, Inthal A, Bauer E, Krapf G, Kaindl U, Kauer M, Dworzak MN, Stoiber D, Haas OA, Panzer-Grümayer R.

Leukemia. 2012 May;26(5):927-33. doi: 10.1038/leu.2011.322. Epub 2011 Nov 18.

PMID:
22094587
26.

The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas.

Schuster C, Berger A, Hoelzl MA, Putz EM, Frenzel A, Simma O, Moritz N, Hoelbl A, Kovacic B, Freissmuth M, Müller M, Villunger A, Müllauer L, Schmatz AI, Streubel B, Porpaczy E, Jäger U, Stoiber D, Sexl V.

Blood. 2011 Oct 27;118(17):4635-45. doi: 10.1182/blood-2010-10-313098. Epub 2011 Aug 30.

27.

Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.

Strobl B, Stoiber D, Sexl V, Mueller M.

Front Biosci (Landmark Ed). 2011 Jun 1;16:3214-32. Review.

PMID:
21622231
28.

A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development.

Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, Rülicke T, Mueller M, Casanova E, Sexl V.

Blood. 2011 Feb 3;117(5):1565-73. doi: 10.1182/blood-2010-06-291633. Epub 2010 Dec 2.

29.

Dendritic cells require STAT-1 phosphorylated at its transactivating domain for the induction of peptide-specific CTL.

Pilz A, Kratky W, Stockinger S, Simma O, Kalinke U, Lingnau K, von Gabain A, Stoiber D, Sexl V, Kolbe T, Rülicke T, Müller M, Decker T.

J Immunol. 2009 Aug 15;183(4):2286-93. doi: 10.4049/jimmunol.0901383. Epub 2009 Jul 20.

30.

Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.

Simma O, Zebedin E, Neugebauer N, Schellack C, Pilz A, Chang-Rodriguez S, Lingnau K, Weisz E, Putz EM, Pickl WF, Felzmann T, Müller M, Decker T, Sexl V, Stoiber D.

Cancer Res. 2009 Jan 1;69(1):203-11. doi: 10.1158/0008-5472.CAN-08-1705.

31.

Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance.

Zebedin E, Simma O, Schuster C, Putz EM, Fajmann S, Warsch W, Eckelhart E, Stoiber D, Weisz E, Schmid JA, Pickl WF, Baumgartner C, Valent P, Piekorz RP, Freissmuth M, Sexl V.

Blood. 2008 Dec 1;112(12):4655-64. doi: 10.1182/blood-2008-02-139105. Epub 2008 Aug 6.

32.

Commentary on H. Ide et al., "Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells".

Schuster C, Müller M, Freissmuth M, Sexl V, Stoiber D.

Biochem Biophys Res Commun. 2008 Feb 22;366(4):869-70. Epub 2007 Dec 17. No abstract available.

PMID:
18082134
33.

STAT1 acts as a tumor promoter for leukemia development.

Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, Levy DE, Beug H, Freissmuth M, Sexl V.

Cancer Cell. 2006 Jul;10(1):77-87.

34.

TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz E, Artwohl M, Kleine OC, Muller M, Baumgartner-Parzer S, Ghysdael J, Freissmuth M, Sexl V.

J Clin Invest. 2004 Dec;114(11):1650-8.

35.

Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T.

Nature. 2003 Jul 31;424(6948):516-23.

PMID:
12872134
36.

Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer.

Khare S, Cerda S, Wali RK, von Lintig FC, Tretiakova M, Joseph L, Stoiber D, Cohen G, Nimmagadda K, Hart J, Sitrin MD, Boss GR, Bissonnette M.

Cancer Res. 2003 Jul 1;63(13):3517-23.

37.

Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation.

Sexl V, Kovacic B, Piekorz R, Moriggl R, Stoiber D, Hoffmeyer A, Liebminger R, Kudlacek O, Weisz E, Rothammer K, Ihle JN.

Blood. 2003 Jun 15;101(12):4937-43. Epub 2003 Feb 6.

38.

Production of type I IFN sensitizes macrophages to cell death induced by Listeria monocytogenes.

Stockinger S, Materna T, Stoiber D, Bayr L, Steinborn R, Kolbe T, Unger H, Chakraborty T, Levy DE, Müller M, Decker T.

J Immunol. 2002 Dec 1;169(11):6522-9.

39.

Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development.

Wali RK, Stoiber D, Nguyen L, Hart J, Sitrin MD, Brasitus T, Bissonnette M.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1316-21.

40.

Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.

Wang HL, Wang J, Xiao SY, Haydon R, Stoiber D, He TC, Bissonnette M, Hart J.

Int J Cancer. 2002 Oct 1;101(4):301-10.

41.
42.

Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway.

Kovarik P, Stoiber D, Eyers PA, Menghini R, Neininger A, Gaestel M, Cohen P, Decker T.

Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13956-61.

43.
44.

Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation.

Kovarik P, Stoiber D, Novy M, Decker T.

EMBO J. 1998 Jul 1;17(13):3660-8. Erratum in: EMBO J 1998 Jul 15;17(14):4210.

45.

Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons.

Meinke A, Barahmand-Pour F, Wöhrl S, Stoiber D, Decker T.

Mol Cell Biol. 1996 Dec;16(12):6937-44.

46.

Platelet dysfunction associated with cardiopulmonary bypass.

Friedenberg WR, Myers WO, Plotka ED, Beathard JN, Kummer DJ, Gatlin PF, Stoiber DL, Ray JF 3rd, Sautter RD.

Ann Thorac Surg. 1978 Apr;25(4):298-305.

PMID:
345986
47.

The origin of the nurse chamber in ovaries ofMiastor (Diptera: Cecidomyidae).

Mahowald AP, Stoiber D.

Wilhelm Roux Arch Entwickl Mech Org. 1974 Dec;176(2):159-166. doi: 10.1007/BF02569025.

PMID:
28304840

Supplemental Content

Loading ...
Support Center